The Evaluation of Effect of Aurora Kinase Inhibitor CCT137690 in Melanoma and Melanoma Cancer Stem Cell
Makaleler > Tam Makale · 2021
Yazarlar: Fatma Sogutlu, Cagla Kayabasi, Besra Ozmen Yelken, Aycan AŞIK, Roya Gasimli, Sezgi Kipcak, Sunde YILMAZ SÜSLÜER, Çığır BİRAY AVCI, Cumhur GÜNDÜZ
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2021, cilt 21, ss 1564-1574
DOI: 10.2174/1871520620666201026155101
Özet
Background: Dysregulation of the cell cycle is one of the main causes of melanomagenesis. Genomewide studies showed that the expression of Aurora-A and-B significantly has been upregulated in melanoma. However, there is no FDA approved drug targeting aurora kinases in the treatment of melanoma. In addition, the development of resistance to chemotherapeutic agents in the treatment of melanoma and, as a result, the relapse due to heterogeneous cell groups in patients is a second phenomenon that causes treatment failure. Therefore, there is an urgent need for therapeutic alternatives targeting both melanoma and melanoma cancer stem cells (MCSCs) in treatments. At this stage, cell cycle regulators become promising targets.